<DOC>
	<DOCNO>NCT02140411</DOCNO>
	<brief_summary>Lucentis® ( ranibizumab ) humanize anti-vascular endothelial growth factor ( VEGF ) monoclonal antibody fragment approve Chile Instituto de Salud Pública treatment diabetic macular edema ( DME ) , retinal vein occlusion age-related macular degeneration . Currently , limit epidemiologic information Chile regard incidence DME limit experience anti-VEGF hospital therapy . This study evaluate efficacy intravitreal ranibizumab Chilean DME patient , investigate anatomical functional improvement follow treatment increase local experience regard use anti-VEGF treatment diabetic macular edema .</brief_summary>
	<brief_title>Efficacy Safety Lucentis® ( Ranibizumab Intravitreal Injections ) Chilean Patients With Diabetic Macular Edema .</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>1 . Diagnosis macular edema due diabetes ( confirm fundus photography , and/or fluorescein angiography , and/or OCT ) least one eye . 2 . Vision impairment due DME ( BCVA ETDRS letter score 4 meter 20 70 letter ( 6/12 3/60 Snellen chart ) . 1 . Laser photocoagulation study eye last 3 month . 2 . Any history intraocular surgery study eye within past 3 month . 3 . Blood pressure &gt; 160/100 mmHg . 4 . Proliferative Diabetic Retinopathy . Any protocol inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>